Revance Therapeutics, Inc. Quarterly Weighted Average Number of Shares Outstanding, Basic from Q1 2013 to Q3 2024

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
Revance Therapeutics, Inc. quarterly/annual Weighted Average Number of Shares Outstanding, Basic history and growth rate from Q1 2013 to Q3 2024.
  • Revance Therapeutics, Inc. Weighted Average Number of Shares Outstanding, Basic for the quarter ending September 30, 2024 was 104M shares, a 20.3% increase year-over-year.
  • Revance Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 84.6M shares, a 16.3% increase from 2022.
  • Revance Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2022 was 72.7M shares, a 7.71% increase from 2021.
  • Revance Therapeutics, Inc. annual Weighted Average Number of Shares Outstanding, Basic for 2021 was 67.5M shares, a 16.4% increase from 2020.
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 104M +17.6M +20.3% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 104M +20.2M +24.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 91.9M +10.8M +13.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 84.6M +11.9M +16.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 86.6M +14.4M +19.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 83.7M +13.6M +19.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 81.1M +12.8M +18.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 72.7M +5.21M +7.71% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 72.2M +4.43M +6.53% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 70.1M +2.6M +3.85% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 68.3M +1.7M +2.55% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 67.5M +9.5M +16.4% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 67.8M +7.26M +12% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 67.5M +13.2M +24.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 66.6M +12.8M +23.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 58M Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 60.5M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 54.3M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 53.9M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q3 2016 28.2M +4.41M +18.5% Jul 1, 2016 Sep 30, 2016 10-Q 2016-11-04
Q2 2016 28.1M +4.5M +19.1% Apr 1, 2016 Jun 30, 2016 10-Q 2016-08-05
Q1 2016 28M +4.47M +19% Jan 1, 2016 Mar 31, 2016 10-Q 2016-05-10
Q4 2015 24.3M +4.95M +25.5% Oct 1, 2015 Dec 31, 2015 10-K 2016-03-04
Q3 2015 23.8M +424K +1.82% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-04
Q2 2015 23.6M +4.2M +21.7% Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-05
Q1 2015 23.5M +12.4M +112% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-10
Q4 2014 19.4M +19.2M +8706% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-04
Q3 2014 23.3M +23.1M +10098% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-10
Q2 2014 19.4M +19.2M +9160% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-07
Q1 2014 11.1M +10.9M +5332% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-14
Q4 2013 220K Oct 1, 2013 Dec 31, 2013 10-K 2016-03-04
Q3 2013 229K Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-13
Q2 2013 209K Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-13
Q1 2013 204K Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.